ARCUTIS BIOTHERAPEUTICS, INC. Income (Loss) Attributable to Parent, before Tax
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Income (Loss) Attributable to Parent, before Tax of $15.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. income (loss) attributable to parent, before tax for the quarter ending 2026-06-30 was $15.14M.
- ARCUTIS BIOTHERAPEUTICS, INC. income (loss) attributable to parent, before tax for the quarter ending 2026-03-31 was -$11.20M.
- ARCUTIS BIOTHERAPEUTICS, INC. income (loss) attributable to parent, before tax for the quarter ending 2025-12-31 was $17.86M.
- ARCUTIS BIOTHERAPEUTICS, INC. income (loss) attributable to parent, before tax for the quarter ending 2025-09-30 was $7.49M.
- ARCUTIS BIOTHERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2025 was -$14.97M.
- ARCUTIS BIOTHERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2024 was -$139.39M.
- ARCUTIS BIOTHERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2023 was -$259.03M.
- ARCUTIS BIOTHERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2022 was -$311.46M.
| Period end | Income (Loss) Attributable to Parent, before Tax 3 month | Income (Loss) Attributable to Parent, before Tax 6 month | Income (Loss) Attributable to Parent, before Tax 9 month | Income (Loss) Attributable to Parent, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.14M 10-Q · filed 2026-08-05 | $3.94M 10-Q · filed 2026-08-05 | $21.81M derived: sum of 3 quarters · filed 2026-08-05 | $29.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$11.20M 10-Q · filed 2026-05-06 | $6.66M derived: sum of 2 quarters · filed 2026-05-06 | $14.15M derived: sum of 3 quarters · filed 2026-05-06 | -$1.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $17.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $25.36M derived: sum of 2 quarters · filed 2026-02-25 | $9.81M derived: sum of 3 quarters · filed 2026-08-05 | -$14.97M 10-K · filed 2026-02-25 |
| 2025-09-30 | $7.49M 10-Q · filed 2025-10-28 | -$8.05M derived: sum of 2 quarters · filed 2026-08-05 | -$32.84M 10-Q · filed 2025-10-28 | -$43.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$15.54M 10-Q · filed 2026-08-05 | -$40.33M 10-Q · filed 2026-08-05 | -$50.79M derived: sum of 3 quarters · filed 2026-08-05 | -$92.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$24.78M 10-Q · filed 2026-05-06 | -$35.25M derived: sum of 2 quarters · filed 2026-05-06 | -$76.78M derived: sum of 3 quarters · filed 2026-05-06 | -$129.12M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$52.00M derived: sum of 2 quarters · filed 2026-02-25 | -$104.33M derived: sum of 3 quarters · filed 2026-02-25 | -$139.39M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$41.54M 10-Q · filed 2025-10-28 | -$93.87M derived: sum of 2 quarters · filed 2025-10-28 | -$128.93M 10-Q · filed 2025-10-28 | -$195.19M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$52.33M 10-Q · filed 2025-08-06 | -$87.39M 10-Q · filed 2025-08-06 | -$153.65M derived: sum of 3 quarters · filed 2026-02-25 | -$195.39M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$35.06M 10-Q · filed 2025-05-06 | -$101.32M derived: sum of 2 quarters · filed 2026-02-25 | -$143.06M derived: sum of 3 quarters · filed 2026-02-25 | -$214.05M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$66.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$108.00M derived: sum of 2 quarters · filed 2026-02-25 | -$178.99M derived: sum of 3 quarters · filed 2026-02-25 | -$259.03M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$41.74M 10-Q · filed 2024-11-06 | -$112.73M derived: sum of 2 quarters · filed 2024-11-06 | -$192.77M 10-Q · filed 2024-11-06 | -$264.85M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$70.99M 10-Q · filed 2024-08-14 | -$151.09M 10-Q · filed 2024-08-14 | -$223.11M derived: sum of 3 quarters · filed 2025-02-25 | -$330.82M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$80.10M 10-Q · filed 2024-05-14 | -$152.12M derived: sum of 2 quarters · filed 2025-02-25 | -$259.83M derived: sum of 3 quarters · filed 2025-02-25 | |
| 2022-12-31 | -$72.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$179.73M derived: sum of 2 quarters · filed 2025-02-25 | -$311.46M 10-K · filed 2025-02-25 | |
| 2022-09-30 | -$107.71M 10-Q · filed 2023-11-03 | -$239.44M 10-Q · filed 2023-11-03 | ||
| 2021-12-31 | -$206.36M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |